In addition, by combining the enantioselectivity-conferring mutation M45F with mutation D114C, which facilitates to immobilize HheG as CLECs, a stable biocatalyst was created exhibiting also improved activity and enantioselectivity. This does not only enhance the industrial applicability of HheG M45F, but further demonstrates that our previously published approach of HheG CLEC formation can be expanded to other HheG variants.